NCT00337194View on ClinicalTrials.gov

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2014

Conditions

Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nodular Sclerosis Hodgkin LymphomaRecurrent Adult Hodgkin Lymphoma

Interventions

BIOLOGICAL

monoclonal antibody SGN-30

Given IV

OTHER

placebo

Given IV

DRUG

vinorelbine tartrate

Given IV

DRUG

pegylated liposomal doxorubicin hydrochloride

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00337194 - SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter